| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ELA1 |
| Uniprot No | P09093 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-270aa |
| 氨基酸序列 | VVHGEDAVPYSWPWQVSLQYEKSGSFYHTCGGSLIAPDWVVTAGHCISRDLTYQVVLGEYNLAVKEGPEQVIPINSEELFVHPLWNRSCVACGNDIALIKLSRSAQLGDAVQLASLPPAGDILPNKTPCYITGWGRLYTNGPLPDKLQQARLPVVDYKHCSRWNWWGSTVKKTMVCAGGYIRSGCNGDSGGPLNCPTEDGGWQVHGVTSFVSAFGCNFIWKPTVFTRVSAFIDWIEETIASH |
| 预测分子量 | 42.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于ELA1重组蛋白的模拟参考文献(注：实际文献请通过PubMed/ScienceDirect等数据库查询)：
1. **文献名称**：Expression and Functional Characterization of Recombinant ELA1 in Inflammatory Response
**作者**：Chen L, et al.
**摘要**：本研究成功在大肠杆菌中表达重组ELA1蛋白酶，并验证其在炎症模型中通过降解细胞外基质调控中性粒细胞迁移的分子机制。
2. **文献名称**：Structural Analysis of ELA1 Mutants for Targeted Cancer Therapy
**作者**：Wang X, et al.
**摘要**：通过X射线晶体学解析ELA1重组蛋白的活性位点结构，设计选择性突变体，体外实验显示其对肿瘤细胞侵袭的抑制作用提升2.3倍。
3. **文献名称**：High-Yield Production of ELA1 in Pichia pastoris and Its Enzymatic Characterization
**作者**：Gupta R, et al.
**摘要**：采用毕赤酵母表达系统实现ELA1重组蛋白的高效分泌表达(产量达1.2g/L)，其比酶活为天然酶的89%，在pH稳定性方面表现优异。
建议通过以下方式获取真实文献：
1. 访问PubMed(https://pubmed.ncbi.nlm.nih.gov/)搜索 "recombinant ELA1 protein"
2. 使用关键词组合："ELA1 elastase recombinant expression purification"
3. 查阅《Protein Expression and Purification》《Biochemical Journal》等相关期刊
ELA1 (elastase 1), also known as neutrophil elastase, is a serine protease encoded by the ELANE gene in humans. It plays a critical role in innate immunity by degrading pathogens and modulating inflammatory responses. Produced primarily by neutrophils, ELA1 cleaves extracellular matrix proteins, including elastin, collagen, and fibronectin, to facilitate immune cell migration and tissue remodeling. However, dysregulated ELA1 activity is linked to tissue damage in chronic inflammatory diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and emphysema. Its unopposed proteolytic action, particularly when alpha-1 antitrypsin (AAT) deficiency occurs, can lead to progressive lung injury.
Recombinant ELA1 refers to the engineered version of this protease produced through genetic modification in heterologous expression systems like Escherichia coli, yeast, or mammalian cells. This approach allows large-scale production with controlled purity and activity, enabling research on its biochemical properties, substrate specificity, and interaction with inhibitors. Recombinant ELA1 is also used to study disease mechanisms and screen therapeutic candidates targeting excessive protease activity. In therapeutic contexts, engineered variants or inhibitors of ELA1 are explored for treating neutrophil-mediated inflammatory disorders. Challenges in its application include ensuring stability, avoiding off-target effects, and optimizing delivery systems.
Recent advances in protein engineering, such as site-directed mutagenesis and glycosylation optimization, aim to enhance recombinant ELA1’s functional consistency and reduce immunogenicity. Its role as a biomarker in neutrophil-associated pathologies further underscores its biomedical relevance. Ongoing research focuses on balancing its dual role as a protective immune mediator and a potential driver of tissue destruction, paving the way for targeted therapies in inflammatory and autoimmune diseases.
×
